Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis

Fineline Cube Feb 2, 2026
Company Deals

Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift

Fineline Cube Feb 2, 2026
Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Policy / Regulatory

FDA Opens PreCheck Applications to Strengthen Domestic Drug Manufacturing

Fineline Cube Feb 2, 2026
Company Drug

Sciwind’s Ecnoglutide Wins NMPA Nod as First cAMP‑Biased GLP‑1 Agonist

Fineline Cube Feb 2, 2026
Company Drug

Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages

Fineline Cube Feb 2, 2026
Company Deals

WinHealth Pharma and Ferring Partner to Co-Promote Pentasa in China

Fineline Cube Jun 16, 2022

China-based Hong Kong WinHealth Pharma Group Ltd has entered into a new partnership with Switzerland-headquartered...

Company Deals

WuXi ATU Partners with Wugen to Accelerate NK Cell Therapy Development

Fineline Cube Jun 16, 2022

WuXi ATU, the gene and cell therapy-focused CTDMO unit of WuXi Apptec (SHA: 603259, HKG:...

Company Drug

Jiangsu Hengrui Medicine’s SHR4640 Receives NMPA Approval for Gout Trial

Fineline Cube Jun 16, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval from the National...

Company Drug

Beijing Aosaikang’s ASKG315 Receives NMPA Approval for Solid Tumor Trial

Fineline Cube Jun 16, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced that its clinical trial application for ASKG315,...

Company Deals

Jacobson Pharma Leads HKD 6 Million JV for Specialty Drug Distribution

Fineline Cube Jun 16, 2022

China-based Jacobson Pharma Corporation (HKG: 2633), Ban Loong Holdings Ltd (HKG: 0030), and JBM (Healthcare)...

Company Drug

Hansoh Pharmaceutical’s Ameile Accepted for UK Regulatory Review

Fineline Cube Jun 16, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a Marketing Authorization Application (MAA)...

Company Deals

MegaRobo Secures USD 300 Million in Series C Round Led by Goldman Sachs

Fineline Cube Jun 16, 2022

Beijing-based MegaRobo Technologies, a company applying robotics and artificial intelligence (AI) in the life sciences...

Policy / Regulatory

China Issues Monkeypox Diagnosis Guidelines Amid Global Outbreaks

Fineline Cube Jun 16, 2022

China’s National Health Commission (NHC) has formulated and released the “Monkeypox Diagnosis and Treatment Guidelines”...

Company Deals

Quoin Pharmaceuticals Partners with WinHealth for Rare Disease Treatments in Greater China

Fineline Cube Jun 16, 2022

US-based rare disease specialist Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) announced a licensing and distribution agreement...

Legal / IP Policy / Regulatory

US Bipartisan Bill Seeks to Regulate Investments in Chinese High-Tech Firms

Fineline Cube Jun 16, 2022

US senators are preparing a bipartisan bill that would require US investors targeting Chinese high-tech...

Company Drug

Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052

Fineline Cube Jun 15, 2022

China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...

Company Drug

Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends

Fineline Cube Jun 15, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...

Company Drug

Jiangsu Hengrui Medicine’s Hetrombopag Olamine Receives FDA Orphan Drug Designation for ITP

Fineline Cube Jun 15, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received orphan...

Company Legal / IP

WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake

Fineline Cube Jun 15, 2022

China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...

Company Drug

Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment

Fineline Cube Jun 15, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...

Company Drug

Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment

Fineline Cube Jun 15, 2022

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...

Company Deals

China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies

Fineline Cube Jun 15, 2022

China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement...

Company Drug

Clover Biopharmaceuticals Initiates SCB-219M Clinical Study for CIT Treatment

Fineline Cube Jun 15, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the first subject dosing in a Phase...

Drug

Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA

Fineline Cube Jun 15, 2022

China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it...

Company Deals

Ferring and I-Mab Expand Olamkicept Collaboration for Inflammatory Diseases

Fineline Cube Jun 14, 2022

Swiss pharmaceutical company Ferring Pharmaceuticals has announced a strategic collaboration with China’s I-Mab Inc. (NASDAQ:...

Posts pagination

1 … 613 614 615 … 617

Recent updates

  • Regeneron Q4 Revenue Grows 3% to $3.9B on EYLEA HD and Dupixent Strength
  • Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis
  • Sciwind’s Ecnoglutide Wins NMPA Nod as First cAMP‑Biased GLP‑1 Agonist
  • FDA Opens PreCheck Applications to Strengthen Domestic Drug Manufacturing
  • Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Regeneron Q4 Revenue Grows 3% to $3.9B on EYLEA HD and Dupixent Strength

Company Deals

Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis

Company Drug

Sciwind’s Ecnoglutide Wins NMPA Nod as First cAMP‑Biased GLP‑1 Agonist

Policy / Regulatory

FDA Opens PreCheck Applications to Strengthen Domestic Drug Manufacturing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.